{"id":"78df0260-ed9f-43bc-a89f-0bc235f011b8","dataset":"sourcesCorporatePublication","time":38,"normalizedUIQL":null,"lastDatasetUpdate":"2019-02-16T00:12:36Z","PagedResults":{"total":1387,"firstRow":141,"lastRow":280,"Result":[{"Field":[{"name":"sourceId","type":"string","value":"1326665"},{"name":"corporatePublicationTitle","type":"string","value":"Meditech's contribution to cancer fight"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-05-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":141},{"Field":[{"name":"sourceId","type":"string","value":"452637"},{"name":"corporatePublicationTitle","type":"string","value":"R&amp;D pipeline: Melan-A/MART-1, dendritic/cancer cell fusion technology, antigen-specific melanoma vaccine, ESO-1 cancer vaccine, aaATIII, p53 gene-based therapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-05-24T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Genzyme Molecular Oncology"}],"pos":142},{"Field":[{"name":"sourceId","type":"string","value":"453087"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: retinoid prophylatic therapy, MD Anderson Cancer Center"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-05-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MD Anderson Cancer Center"}],"pos":143},{"Field":[{"name":"sourceId","type":"string","value":"453815"},{"name":"corporatePublicationTitle","type":"string","value":"Intercell: pipeline validation; cancer vaccine (Phase I), HCV vaccine (phase II), Tuberculosis vaccine (DR)"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-06-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Intercell Biomedical Research & Development GmbH"}],"pos":144},{"Field":[{"name":"sourceId","type":"string","value":"455169"},{"name":"corporatePublicationTitle","type":"string","value":"Treatments for colorectal cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-06-19T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Wellstat Therapeutics"}],"pos":145},{"Field":[{"name":"sourceId","type":"string","value":"455168"},{"name":"corporatePublicationTitle","type":"string","value":"Treatment for Gastric Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-06-19T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Wellstat Therapeutics"}],"pos":146},{"Field":[{"name":"sourceId","type":"string","value":"455166"},{"name":"corporatePublicationTitle","type":"string","value":"Treatments for Pancreatic Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-06-19T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Wellstat Therapeutics"}],"pos":147},{"Field":[{"name":"sourceId","type":"string","value":"457075"},{"name":"corporatePublicationTitle","type":"string","value":"Review of the use of SRL-172 in the treatment of cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-07-02T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SR Pharma plc"}],"pos":148},{"Field":[{"name":"sourceId","type":"string","value":"456821"},{"name":"corporatePublicationTitle","type":"string","value":"SRL-172 in cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-07-02T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SR Pharma plc"}],"pos":149},{"Field":[{"name":"sourceId","type":"string","value":"458836"},{"name":"corporatePublicationTitle","type":"string","value":"Celsion, new cancer drugs"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-07-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Celsion Corp"}],"pos":150},{"Field":[{"name":"sourceId","type":"string","value":"461769"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: DeImmunized Abs (colon cancer), Biovation/CRC"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-08-19T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Biovation Ltd"}],"pos":151},{"Field":[{"name":"sourceId","type":"string","value":"462701"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer drug discovery"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-08-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Tosk Inc"}],"pos":152},{"Field":[{"name":"sourceId","type":"string","value":"462611"},{"name":"corporatePublicationTitle","type":"string","value":"Clinical Trials"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-08-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":153},{"Field":[{"name":"sourceId","type":"string","value":"465468"},{"name":"corporatePublicationTitle","type":"string","value":"Oxomate for Cancer Chemoprevention via Induction of Phase II Detoxification Enzymes: Protecting the body from chemical carcinogenesis reduces the risk of developing cancers in the breast, lung, and colon"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-09-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"University of Illinois"}],"pos":154},{"Field":[{"name":"sourceId","type":"string","value":"488594"},{"name":"corporatePublicationTitle","type":"string","value":"R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-09-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institutes of Health"}],"pos":155},{"Field":[{"name":"sourceId","type":"string","value":"465469"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: HuMax-CD4, HuMax-IL15, HuMax-Inflam, HuMax-EGFr, HuMax-Cancer, HuMax-Lymphoma"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-09-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Genmab A/S"}],"pos":156},{"Field":[{"name":"sourceId","type":"string","value":"467384"},{"name":"corporatePublicationTitle","type":"string","value":"Innovation in cancer and liver disease. Focus on commercialization"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-10-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Maxim Pharmaceuticals Inc"}],"pos":157},{"Field":[{"name":"sourceId","type":"string","value":"467305"},{"name":"corporatePublicationTitle","type":"string","value":"EP32.1.2 cancer drug target profile"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-10-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Europroteome AG"}],"pos":158},{"Field":[{"name":"sourceId","type":"string","value":"467303"},{"name":"corporatePublicationTitle","type":"string","value":"EP23.21 cancer drug target profile"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-10-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Europroteome AG"}],"pos":159},{"Field":[{"name":"sourceId","type":"string","value":"467299"},{"name":"corporatePublicationTitle","type":"string","value":"Europroteome the human cancer company"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-10-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Europroteome AG"}],"pos":160},{"Field":[{"name":"sourceId","type":"string","value":"467271"},{"name":"corporatePublicationTitle","type":"string","value":"Partnering Opportunity: EP-2101, t-cell epitope-based vaccine for the treatment of breast, colon and lung cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-10-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Epimmune Inc"}],"pos":161},{"Field":[{"name":"sourceId","type":"string","value":"467876"},{"name":"corporatePublicationTitle","type":"string","value":"Intraperitoneal Administration of the Radiolabelled Monoclonal Antibody Pemtumomab (Yttrium-90-HMFG1) in Gastric Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-10-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Murawa P"}],"pos":162},{"Field":[{"name":"sourceId","type":"string","value":"470838"},{"name":"corporatePublicationTitle","type":"string","value":"Company presentation: Immunomedics Inc. - Focused on antibody therapies for cancer, autoimmune and infectious diseases"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-11-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Immunomedics Inc"}],"pos":163},{"Field":[{"name":"sourceId","type":"string","value":"469389"},{"name":"corporatePublicationTitle","type":"string","value":"Professor Freda Stevenson - Genetic Vaccines Against Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-11-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Southampton University"}],"pos":164},{"Field":[{"name":"sourceId","type":"string","value":"469749"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Depocyt, Proleukin, HIV vaccine (clade B), HCV vaccine (1), HCV vaccine (2), HCV vaccine (3), Lexigen cancer vaccine"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-11-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Chiron Corp"}],"pos":165},{"Field":[{"name":"sourceId","type":"string","value":"480127"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Advisory Committee requests further data on AstraZeneca's CASODEX (bicalutamide) 150mg for early prostate cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-12-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"AstraZeneca"}],"pos":166},{"Field":[{"name":"sourceId","type":"string","value":"641350"},{"name":"corporatePublicationTitle","type":"string","value":"Major Accomplishments of the Developmental Therapeutics Program"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":167},{"Field":[{"name":"sourceId","type":"string","value":"485415"},{"name":"corporatePublicationTitle","type":"string","value":"TSRI News: anti-cancer nanoparticles: TSRI scientists design gene-tipped tumor regressor \"smartbombs\""},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Scripps Research Institute"}],"pos":168},{"Field":[{"name":"sourceId","type":"string","value":"475162"},{"name":"corporatePublicationTitle","type":"string","value":"COU-1. An all-human anti-adenocarcinoma antibody for cancer detection and therapy"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"NatImmune A/S"}],"pos":169},{"Field":[{"name":"sourceId","type":"string","value":"490850"},{"name":"corporatePublicationTitle","type":"string","value":"Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-01-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institutes of Health"}],"pos":170},{"Field":[{"name":"sourceId","type":"string","value":"518283"},{"name":"corporatePublicationTitle","type":"string","value":"S-dimethylarsino-glutathione"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-01-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MD Anderson Cancer Center"}],"pos":171},{"Field":[{"name":"sourceId","type":"string","value":"475757"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: G250 antibodies"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-01-09T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ludwig Institute for Cancer Research"}],"pos":172},{"Field":[{"name":"sourceId","type":"string","value":"506827"},{"name":"corporatePublicationTitle","type":"string","value":"New and emerging technology briefing: ISIS-3521 (Affinitak) for non-small cell lung cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-01-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"The University of Birmingham"}],"pos":173},{"Field":[{"name":"sourceId","type":"string","value":"476726"},{"name":"corporatePublicationTitle","type":"string","value":"Allos Therapeutics Inc - Innovation in Cancer Therapy - presentation at the JPMorgan H&amp;Q 21st Annual Heathcare Conference"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-01-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":174},{"Field":[{"name":"sourceId","type":"string","value":"476299"},{"name":"corporatePublicationTitle","type":"string","value":"SeattleGenetics - mab therapies for cancer - presentation at the JPMorgan H&amp;Q 21st Annual Healthcare Conference"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-01-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":175},{"Field":[{"name":"sourceId","type":"string","value":"478221"},{"name":"corporatePublicationTitle","type":"string","value":"Peptide-liposome technology"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-02-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"CTT Cancer Targeting Technologies Oy"}],"pos":176},{"Field":[{"name":"sourceId","type":"string","value":"478518"},{"name":"corporatePublicationTitle","type":"string","value":"Projects"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-02-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"G2M Cancer Drugs AG"}],"pos":177},{"Field":[{"name":"sourceId","type":"string","value":"478516"},{"name":"corporatePublicationTitle","type":"string","value":"Company info"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-02-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"G2M Cancer Drugs AG"}],"pos":178},{"Field":[{"name":"sourceId","type":"string","value":"490847"},{"name":"corporatePublicationTitle","type":"string","value":"Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-03-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Institutes of Health"}],"pos":179},{"Field":[{"name":"sourceId","type":"string","value":"484166"},{"name":"corporatePublicationTitle","type":"string","value":"Technologies in Development: Anticancer - A Sigma Ligand for Breast Cancer Imaging and Therapy - PIMBA, a sigma ligand for breast cancer imaging and therapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-03-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Research Corp Technologies Inc"}],"pos":180},{"Field":[{"name":"sourceId","type":"string","value":"481513"},{"name":"corporatePublicationTitle","type":"string","value":"Xenova: PAI-1 inhibitors - Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-03-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Xenova Group plc"}],"pos":181},{"Field":[{"name":"sourceId","type":"string","value":"484417"},{"name":"corporatePublicationTitle","type":"string","value":"Patient Information > Pediatric Cancer Care > Pediatric Cancers > Types of Cancer > Neuroblastoma > 3F8 Monoclonal Antibody Therapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-04-02T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Memorial Sloan-Kettering Cancer Center"}],"pos":182},{"Field":[{"name":"sourceId","type":"string","value":"484918"},{"name":"corporatePublicationTitle","type":"string","value":"Drug licensing: PK1"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-04-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research UK"}],"pos":183},{"Field":[{"name":"sourceId","type":"string","value":"485458"},{"name":"corporatePublicationTitle","type":"string","value":"Products: Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-04-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Synta Pharmaceuticals Corp"}],"pos":184},{"Field":[{"name":"sourceId","type":"string","value":"487451"},{"name":"corporatePublicationTitle","type":"string","value":"Communication regarding the development of PK1"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-04-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research UK"}],"pos":185},{"Field":[{"name":"sourceId","type":"string","value":"493788"},{"name":"corporatePublicationTitle","type":"string","value":"Intercell for Vaccperts > Products > Bladder cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-06-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Intercell AG"}],"pos":186},{"Field":[{"name":"sourceId","type":"string","value":"514161"},{"name":"corporatePublicationTitle","type":"string","value":"Novuspharma SpA R&amp;D: Professional Information, hormone refractory prostate cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-06-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Novuspharma SpA"}],"pos":187},{"Field":[{"name":"sourceId","type":"string","value":"536425"},{"name":"corporatePublicationTitle","type":"string","value":"Detailed Guide: Myelodysplastic Syndrome: What Are The Key Statistics About Myelodysplastic Syndrome?"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-06-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"American Cancer Societ"}],"pos":188},{"Field":[{"name":"sourceId","type":"string","value":"493020"},{"name":"corporatePublicationTitle","type":"string","value":"Clinical Trials- Skin and Melanoma: E1696, Phase II evaluation of immunization with an HLA-A2 multi-epitope peptide vaccine containing MART-1 (NSC672643), gp100(NSC683472), and tyrosinase (NSC699048) peptides alone or in combination with GM-CSF, IFNalfa2b or GM-CSF +IFNalfa2b in patients with metastatic melanoma"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-06-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Emory- Winship cancer Institute"}],"pos":189},{"Field":[{"name":"sourceId","type":"string","value":"494391"},{"name":"corporatePublicationTitle","type":"string","value":"A new option for cancer patients: Advanced pain management with transdermal buprenorphine (Transtec)"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-06-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Gruenenthal GmbH"}],"pos":190},{"Field":[{"name":"sourceId","type":"string","value":"944637"},{"name":"corporatePublicationTitle","type":"string","value":"The Positioning of Capecitabine for Breast Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-07-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Chugai Pharmaceutical Co Ltd"}],"pos":191},{"Field":[{"name":"sourceId","type":"string","value":"497231"},{"name":"corporatePublicationTitle","type":"string","value":"Business Area: Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-07-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"IDRTech Inc"}],"pos":192},{"Field":[{"name":"sourceId","type":"string","value":"509141"},{"name":"corporatePublicationTitle","type":"string","value":"CCR Frontiers in Science"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-07-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":193},{"Field":[{"name":"sourceId","type":"string","value":"498156"},{"name":"corporatePublicationTitle","type":"string","value":"Corvas International - protease activated cancer therapy (PACT) program"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-07-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Corvas International Inc"}],"pos":194},{"Field":[{"name":"sourceId","type":"string","value":"499083"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline update: CTL-102 + CB-1954; CTL-203 + CB-1954; CTL-301 + CB-1954; CTL-501; dendritic cell therapy (cancer), ML Laboratories"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-07-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ML Laboratories plc"}],"pos":195},{"Field":[{"name":"sourceId","type":"string","value":"500893"},{"name":"corporatePublicationTitle","type":"string","value":"Prodrugs for CNS cancers"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-08-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Amedis Pharmaceuticals Ltd"}],"pos":196},{"Field":[{"name":"sourceId","type":"string","value":"529970"},{"name":"corporatePublicationTitle","type":"string","value":"Phase II Study of TLK286 (GST P1-1 Activated Glutathione Analog) Administered Weekly in Patients with Platinum Refractory or Resistance Non-Small Cell Lung Cancer (NSCLC)"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-08-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Telik Inc"}],"pos":197},{"Field":[{"name":"sourceId","type":"string","value":"508270"},{"name":"corporatePublicationTitle","type":"string","value":"Aegera Therapeutics Inc - extending and enhancing the lives of cancer patients"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-10-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Aegera Therapeutics Inc"}],"pos":198},{"Field":[{"name":"sourceId","type":"string","value":"516744"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development profile: NSC-726190"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-12-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":199},{"Field":[{"name":"sourceId","type":"string","value":"517441"},{"name":"corporatePublicationTitle","type":"string","value":"Maxygen - Colorectal cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-12-09T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Maxygen Inc"}],"pos":200},{"Field":[{"name":"sourceId","type":"string","value":"670976"},{"name":"corporatePublicationTitle","type":"string","value":"Company website pipeline: Ludwig Institute for Cancer Research"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-12-19T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ludwig Institute for Cancer Research"}],"pos":201},{"Field":[{"name":"sourceId","type":"string","value":"601721"},{"name":"corporatePublicationTitle","type":"string","value":"Medicinal Chemistry &amp; Molecular Modelling: Cancer Drug Discovery and Development"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-01-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"University of Nottingham"}],"pos":202},{"Field":[{"name":"sourceId","type":"string","value":"567095"},{"name":"corporatePublicationTitle","type":"string","value":"Company Profile"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-01-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":203},{"Field":[{"name":"sourceId","type":"string","value":"532863"},{"name":"corporatePublicationTitle","type":"string","value":"Development Programs - Cancer Therapeutics"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-02-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Progen Industries Ltd"}],"pos":204},{"Field":[{"name":"sourceId","type":"string","value":"530902"},{"name":"corporatePublicationTitle","type":"string","value":"NCI Cancer Bulletin"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-02-24T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":205},{"Field":[{"name":"sourceId","type":"string","value":"545740"},{"name":"corporatePublicationTitle","type":"string","value":"About Cell Therapeutics Cancer Research, Cancer Therapies and Cancer Drug Development"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-02-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cell Therapeutics Inc"}],"pos":206},{"Field":[{"name":"sourceId","type":"string","value":"565213"},{"name":"corporatePublicationTitle","type":"string","value":"TG-4010: Cancer vaccine to treat MUC1 positive tumors"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-02-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Transgene SA"}],"pos":207},{"Field":[{"name":"sourceId","type":"string","value":"527591"},{"name":"corporatePublicationTitle","type":"string","value":"making existing treatments better"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-03-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Australian Cancer Technology Ltd"}],"pos":208},{"Field":[{"name":"sourceId","type":"string","value":"529538"},{"name":"corporatePublicationTitle","type":"string","value":"Vion - Cancer Drug Discovery and Development - Products in Clinical Trials"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-03-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Vion Pharmaceuticals Inc"}],"pos":209},{"Field":[{"name":"sourceId","type":"string","value":"637354"},{"name":"corporatePublicationTitle","type":"string","value":"Targeted cancer chemotherapy using prodrugs"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-03-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Proacta Therapeutics Ltd; University of Auckland"}],"pos":210},{"Field":[{"name":"sourceId","type":"string","value":"531278"},{"name":"corporatePublicationTitle","type":"string","value":"Products - Therapeutics for cancer and viral infections; therapeutics for autoimmune diseases"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-04-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Altor Bioscience Corp"}],"pos":211},{"Field":[{"name":"sourceId","type":"string","value":"586533"},{"name":"corporatePublicationTitle","type":"string","value":"Drug discovery and development at the cancer center"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-04-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"University of Alabama at Birmingham"}],"pos":212},{"Field":[{"name":"sourceId","type":"string","value":"537603"},{"name":"corporatePublicationTitle","type":"string","value":"New approaches to cancer therapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-05-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pivotal BioSciences Inc"}],"pos":213},{"Field":[{"name":"sourceId","type":"string","value":"538377"},{"name":"corporatePublicationTitle","type":"string","value":"NovaRx Pipeline: Our Technology to fight cancer, Scientific Abstracts"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-05-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"NovaRx Corp"}],"pos":214},{"Field":[{"name":"sourceId","type":"string","value":"538952"},{"name":"corporatePublicationTitle","type":"string","value":"Memorial Sloan-Kettering Cancer Center"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-05-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Memorial Sloan-Kettering Cancer Center"}],"pos":215},{"Field":[{"name":"sourceId","type":"string","value":"657915"},{"name":"corporatePublicationTitle","type":"string","value":"igeneon - immunotherapy of cancer BIO 2004"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-06-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Igeneon AG"}],"pos":216},{"Field":[{"name":"sourceId","type":"string","value":"545482"},{"name":"corporatePublicationTitle","type":"string","value":"Vaccine treatment for advanced non-small-cell lung cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-06-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"The Food and Drug Administration"}],"pos":217},{"Field":[{"name":"sourceId","type":"string","value":"545478"},{"name":"corporatePublicationTitle","type":"string","value":"NewLink Genetics - Core Technologies - HyperAcute Cancer Vaccines"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-06-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"NewLink Genetics Corp"}],"pos":218},{"Field":[{"name":"sourceId","type":"string","value":"545556"},{"name":"corporatePublicationTitle","type":"string","value":"Overview of the Kimmel Cancer Center for Patients and Families"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-06-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Thomas Jefferson University"}],"pos":219},{"Field":[{"name":"sourceId","type":"string","value":"545509"},{"name":"corporatePublicationTitle","type":"string","value":"About Dana-Farber"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-06-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Dana-Farber Cancer Institute Inc"}],"pos":220},{"Field":[{"name":"sourceId","type":"string","value":"572379"},{"name":"corporatePublicationTitle","type":"string","value":"Publications: Leukemia insights newsletter"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-06-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MD Anderson Cancer Center"}],"pos":221},{"Field":[{"name":"sourceId","type":"string","value":"547527"},{"name":"corporatePublicationTitle","type":"string","value":"Xenova innovation in cancer and immunotherapy R&amp;D day"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-07-02T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Xenova Group plc"}],"pos":222},{"Field":[{"name":"sourceId","type":"string","value":"550347"},{"name":"corporatePublicationTitle","type":"string","value":"About us"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-07-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Roswell Park Cancer Institute"}],"pos":223},{"Field":[{"name":"sourceId","type":"string","value":"550847"},{"name":"corporatePublicationTitle","type":"string","value":"WWW Homepage: The Ludwig Institute of Cancer Research"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-07-26T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ludwig Institute for Cancer Research"}],"pos":224},{"Field":[{"name":"sourceId","type":"string","value":"559960"},{"name":"corporatePublicationTitle","type":"string","value":"Broad-spectrum, targeted approaches to cancer treatment"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-07-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ArQule Inc"}],"pos":225},{"Field":[{"name":"sourceId","type":"string","value":"596416"},{"name":"corporatePublicationTitle","type":"string","value":"MT103 family of therapeutic compounds - Treatment for Non-small Cell Lung Cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-08-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Medisyn Technologies Inc"}],"pos":226},{"Field":[{"name":"sourceId","type":"string","value":"602494"},{"name":"corporatePublicationTitle","type":"string","value":"2004 Annual Report - MD Anderson Cancer Center"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-08-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MD Anderson Cancer Center"}],"pos":227},{"Field":[{"name":"sourceId","type":"string","value":"557834"},{"name":"corporatePublicationTitle","type":"string","value":"ArQule's novel approach to cancer: Activated checkpoint therapy program"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-09-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ArQule Inc"}],"pos":228},{"Field":[{"name":"sourceId","type":"string","value":"1232046"},{"name":"corporatePublicationTitle","type":"string","value":"Antitumor activity of Pulsatilla saponins against some cancer cell lines and mice bearing LL-2"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-09-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SBPharmaceutical IND Co Ltd"}],"pos":229},{"Field":[{"name":"sourceId","type":"string","value":"558759"},{"name":"corporatePublicationTitle","type":"string","value":"The cancer market"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-09-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Solbec Pharmaceuticals Ltd"}],"pos":230},{"Field":[{"name":"sourceId","type":"string","value":"558903"},{"name":"corporatePublicationTitle","type":"string","value":"Corporate fact sheet: developing and commercializing diverse portfolio of cancer therapies"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-09-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ZIOPHARM Inc"}],"pos":231},{"Field":[{"name":"sourceId","type":"string","value":"575893"},{"name":"corporatePublicationTitle","type":"string","value":"Adherex Technologies Inc: Annual report 2004 - Pioneering innovative cancer treatments"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-09-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Adherex Technologies Inc"}],"pos":232},{"Field":[{"name":"sourceId","type":"string","value":"616339"},{"name":"corporatePublicationTitle","type":"string","value":"Australian Cancer Technology Ltd: Annual report 2004"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-09-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Avantogen Ltd"}],"pos":233},{"Field":[{"name":"sourceId","type":"string","value":"560316"},{"name":"corporatePublicationTitle","type":"string","value":"Sidney Kimmel Cancer Center - About the Center"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-09-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Sidney Kimmel Cancer Center"}],"pos":234},{"Field":[{"name":"sourceId","type":"string","value":"583487"},{"name":"corporatePublicationTitle","type":"string","value":"SCR0044001: A novel anti-cancer compound"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-09-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"BioImage A/S"}],"pos":235},{"Field":[{"name":"sourceId","type":"string","value":"561646"},{"name":"corporatePublicationTitle","type":"string","value":"Reata Discovery Inc - Discovery and Developing Therapeutics for Cancers and Neurodegenerative Diseases"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-09-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Reata Discovery Inc"}],"pos":236},{"Field":[{"name":"sourceId","type":"string","value":"561847"},{"name":"corporatePublicationTitle","type":"string","value":"EB-1627 for treatment of small cell lung cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-10-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"LEO Pharma A/S"}],"pos":237},{"Field":[{"name":"sourceId","type":"string","value":"563353"},{"name":"corporatePublicationTitle","type":"string","value":"Triton BioSystems: Creating low side effect cancer treatments"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-10-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Triton BioSystems Inc"}],"pos":238},{"Field":[{"name":"sourceId","type":"string","value":"564747"},{"name":"corporatePublicationTitle","type":"string","value":"Seattle Genetics - mAb therapies for cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-10-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Seattle Genetics Inc"}],"pos":239},{"Field":[{"name":"sourceId","type":"string","value":"565038"},{"name":"corporatePublicationTitle","type":"string","value":"About us- Addressing the Unmet Needs of Cancer Patients"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-10-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":240},{"Field":[{"name":"sourceId","type":"string","value":"566413"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development: safingol"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-10-19T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Memorial Sloan-Kettering Cancer Center"}],"pos":241},{"Field":[{"name":"sourceId","type":"string","value":"565976"},{"name":"corporatePublicationTitle","type":"string","value":"About the Center"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-10-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Garden State Cancer Center"}],"pos":242},{"Field":[{"name":"sourceId","type":"string","value":"567637"},{"name":"corporatePublicationTitle","type":"string","value":"ArQule Inc: \"molecules to medicines\" - activating checkpoints to selectively kill cancer cells"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-10-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ArQule Inc"}],"pos":243},{"Field":[{"name":"sourceId","type":"string","value":"570646"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer Programs - Topo I Inhibitors"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-11-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Reata Discovery Inc"}],"pos":244},{"Field":[{"name":"sourceId","type":"string","value":"570831"},{"name":"corporatePublicationTitle","type":"string","value":"Research: Clinical: Medicine Section"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-11-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"The Institute Of Cancer Research"}],"pos":245},{"Field":[{"name":"sourceId","type":"string","value":"605734"},{"name":"corporatePublicationTitle","type":"string","value":"News and Events: CellGenix GmbH receives EU- orphan drug status for IdioVax cancer vaccine"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-11-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":246},{"Field":[{"name":"sourceId","type":"string","value":"573454"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer Institute - Outline"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-11-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Japanese Foundation For Cancer Research"}],"pos":247},{"Field":[{"name":"sourceId","type":"string","value":"575234"},{"name":"corporatePublicationTitle","type":"string","value":"Vaxon Biotech: Development of optimized cryptic peptides for cancer immunotherapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-12-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Vaxon Biotech SA"}],"pos":248},{"Field":[{"name":"sourceId","type":"string","value":"575541"},{"name":"corporatePublicationTitle","type":"string","value":"Who we are: about Cancer Research UK"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-12-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Research UK"}],"pos":249},{"Field":[{"name":"sourceId","type":"string","value":"575530"},{"name":"corporatePublicationTitle","type":"string","value":"CANCER VAC: Cancer immunotherapy project"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-12-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Prima Biomed Ltd"}],"pos":250},{"Field":[{"name":"sourceId","type":"string","value":"576655"},{"name":"corporatePublicationTitle","type":"string","value":"About the Institute: history of the John Wayne Cancer Institute"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-12-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"John Wayne Cancer Institute"}],"pos":251},{"Field":[{"name":"sourceId","type":"string","value":"603742"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer Vaccine Collaborative"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ludwig Institute for Cancer Research"}],"pos":252},{"Field":[{"name":"sourceId","type":"string","value":"594068"},{"name":"corporatePublicationTitle","type":"string","value":"Institut Pasteur: Annual Report of Liver Cancer and Molecular Virology for Year 2004"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Institut Pasteur"}],"pos":253},{"Field":[{"name":"sourceId","type":"string","value":"580643"},{"name":"corporatePublicationTitle","type":"string","value":"Clinical Trials updates"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Lee Moffitt Cancer Center and Research Institute"}],"pos":254},{"Field":[{"name":"sourceId","type":"string","value":"600940"},{"name":"corporatePublicationTitle","type":"string","value":"Company website"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-01-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Faustus Forschungs Cie Translational Cancer Research GmbH"}],"pos":255},{"Field":[{"name":"sourceId","type":"string","value":"594223"},{"name":"corporatePublicationTitle","type":"string","value":"Company website"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-01-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"CTT Cancer Targeting Technologies Oy"}],"pos":256},{"Field":[{"name":"sourceId","type":"string","value":"591085"},{"name":"corporatePublicationTitle","type":"string","value":"Company profile"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-01-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cancer Therapy & Research Center"}],"pos":257},{"Field":[{"name":"sourceId","type":"string","value":"1015796"},{"name":"corporatePublicationTitle","type":"string","value":"Phase I/II prostate cancer pilot clinical trial begins"},{"name":"corporatePublicationType","type":"string","value":"Company Newsletter"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-01-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"IC-MedTech Inc"}],"pos":258},{"Field":[{"name":"sourceId","type":"string","value":"578622"},{"name":"corporatePublicationTitle","type":"string","value":"About EORTC - Organisation Activities and Current Research: Aims, History, Presidents"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-01-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"European Organisation for Research and Treatment of Cancer (EORTC)"}],"pos":259},{"Field":[{"name":"sourceId","type":"string","value":"578517"},{"name":"corporatePublicationTitle","type":"string","value":"Company info"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-01-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"G2M Cancer Drugs AG"}],"pos":260},{"Field":[{"name":"sourceId","type":"string","value":"584434"},{"name":"corporatePublicationTitle","type":"string","value":"Vion Pharmaceuticals Inc: Cancer Treatment Technologies: Core technologies: Heterocyclic Hydrazones"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-02-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Vion Pharmaceuticals Inc"}],"pos":261},{"Field":[{"name":"sourceId","type":"string","value":"586309"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer Therapeutics from FASgen"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-02-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"FASgen Inc"}],"pos":262},{"Field":[{"name":"sourceId","type":"string","value":"587759"},{"name":"corporatePublicationTitle","type":"string","value":"Projects: product development"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-03-02T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"G2M Cancer Drugs AG"}],"pos":263},{"Field":[{"name":"sourceId","type":"string","value":"599838"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Report 2004 - Cell Therapeutics Inc: Together We Are Redefining The Landscape of Cancer Therapies"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-03-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cell Therapeutics Inc"}],"pos":264},{"Field":[{"name":"sourceId","type":"string","value":"588555"},{"name":"corporatePublicationTitle","type":"string","value":"TELOMERES AND TELOMERASE IN CELL AGING AND CANCER"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-03-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Geron Corp"}],"pos":265},{"Field":[{"name":"sourceId","type":"string","value":"591091"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer drug development"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-03-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"PharmaGap Inc"}],"pos":266},{"Field":[{"name":"sourceId","type":"string","value":"597089"},{"name":"corporatePublicationTitle","type":"string","value":"uacc: content store: Phase 1"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-03-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Colorado State University: Cancer Center"}],"pos":267},{"Field":[{"name":"sourceId","type":"string","value":"671026"},{"name":"corporatePublicationTitle","type":"string","value":"StressGen annual report 2004: Harnessing the power of the immune system to treat viral diseases and cancer"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-04-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Nventa Biopharmaceuticals Corp"}],"pos":268},{"Field":[{"name":"sourceId","type":"string","value":"597419"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development piepline: benzaldehyde dimethane sulfonate"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-04-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":269},{"Field":[{"name":"sourceId","type":"string","value":"597459"},{"name":"corporatePublicationTitle","type":"string","value":"University of Pittsburgh Cancer Institute: Selected projects"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-04-26T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":270},{"Field":[{"name":"sourceId","type":"string","value":"597807"},{"name":"corporatePublicationTitle","type":"string","value":"Auristatin PYE: A Novel Anti-Cancer Compound"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-04-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Arizona State University"}],"pos":271},{"Field":[{"name":"sourceId","type":"string","value":"599147"},{"name":"corporatePublicationTitle","type":"string","value":"Product Portfolio: DOS47 Cancer Therapeutic"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-05-03T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Helix BioPharma Corp"}],"pos":272},{"Field":[{"name":"sourceId","type":"string","value":"599873"},{"name":"corporatePublicationTitle","type":"string","value":"RTA  401/402: Synthetic Triterpenoids for Treating Hematological Cancers and Solid Tumors"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-05-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Reata Pharmaceuticals Inc"}],"pos":273},{"Field":[{"name":"sourceId","type":"string","value":"601202"},{"name":"corporatePublicationTitle","type":"string","value":"Division of Cancer Prevention"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-05-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":274},{"Field":[{"name":"sourceId","type":"string","value":"909374"},{"name":"corporatePublicationTitle","type":"string","value":"Clinical trials. Phase III Randomized Study of Adjuvant Chemotherapy Comprising Fluorouracil, Leucovorin Calcium, and Oxaliplatin With Versus Without Bevacizumab in Patients With Resected Stage II or III Adenocarcinoma of the Colon"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-05-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"National Cancer Institute"}],"pos":275},{"Field":[{"name":"sourceId","type":"string","value":"606152"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: immunotherapy (multidrug resistant cancer), AC Immune"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-06-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"AC Immune SA"}],"pos":276},{"Field":[{"name":"sourceId","type":"string","value":"610277"},{"name":"corporatePublicationTitle","type":"string","value":"Turning human cells into cancer therapies"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-06-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ZellerRx Corp"}],"pos":277},{"Field":[{"name":"sourceId","type":"string","value":"658212"},{"name":"corporatePublicationTitle","type":"string","value":"Mobilizing the body's defences - IGN101 therapeutic cancer vaccine"},{"name":"corporatePublicationType","type":"string","value":"Company Newsletter"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-06-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Igeneon GmbH"}],"pos":278},{"Field":[{"name":"sourceId","type":"string","value":"672282"},{"name":"corporatePublicationTitle","type":"string","value":"Transgene SA: Annual report 2005 \"Immunotherapy to Fight Cancer and Infectious Diseases\""},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-07-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Transgene SA"}],"pos":279},{"Field":[{"name":"sourceId","type":"string","value":"612785"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development: LBH-589"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-07-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"San Antonio Cancer Institute"}],"pos":280}]},"DatasetCounts":[],"HitTerms":{"Term":[{"value":"cancer"}],"Synonym":[{"value":"cancers"},{"value":"chemotherapy resistant tumor"},{"value":"malignant neoplastic disease"},{"value":"refractory pediatric cancer"}]},"serviceExecutionTime":48}